Timothy Eugene Sullivan Sells 4,000 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLSGet Free Report) CFO Timothy Eugene Sullivan sold 4,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $58.66, for a total transaction of $234,640.00. Following the completion of the transaction, the chief financial officer now directly owns 93,338 shares in the company, valued at $5,475,207.08. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Timothy Eugene Sullivan also recently made the following trade(s):

  • On Friday, March 1st, Timothy Eugene Sullivan sold 6,000 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $63.22, for a total transaction of $379,320.00.
  • On Monday, February 12th, Timothy Eugene Sullivan sold 1,431 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $67.77, for a total transaction of $96,978.87.
  • On Monday, January 22nd, Timothy Eugene Sullivan sold 3,551 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $65.00, for a total transaction of $230,815.00.
  • On Tuesday, January 16th, Timothy Eugene Sullivan sold 2,235 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $66.81, for a total transaction of $149,320.35.

Apellis Pharmaceuticals Stock Up 2.2 %

Apellis Pharmaceuticals stock opened at $56.95 on Thursday. The firm has a 50 day moving average price of $62.84 and a two-hundred day moving average price of $56.34. The firm has a market cap of $6.87 billion, a price-to-earnings ratio of -12.71 and a beta of 0.88. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.50 and a current ratio of 3.10. Apellis Pharmaceuticals, Inc. has a 52-week low of $19.83 and a 52-week high of $94.75.

Apellis Pharmaceuticals (NASDAQ:APLSGet Free Report) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.73) earnings per share for the quarter, meeting the consensus estimate of ($0.73). The company had revenue of $146.38 million during the quarter, compared to analyst estimates of $143.34 million. Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. Apellis Pharmaceuticals’s revenue for the quarter was up 545.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.50) EPS. Equities analysts predict that Apellis Pharmaceuticals, Inc. will post -1.36 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $92.00 price target on shares of Apellis Pharmaceuticals in a research note on Wednesday, February 28th. Citigroup cut their target price on shares of Apellis Pharmaceuticals from $70.00 to $67.00 and set a “buy” rating on the stock in a research report on Friday, December 15th. Mizuho reiterated a “neutral” rating and set a $60.00 target price on shares of Apellis Pharmaceuticals in a research report on Wednesday, March 27th. Jefferies Financial Group upgraded shares of Apellis Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their target price for the stock from $68.00 to $80.00 in a research report on Monday, February 5th. Finally, Wells Fargo & Company downgraded shares of Apellis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $67.00 to $54.00 in a research report on Thursday, December 14th. Three investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $77.93.

Get Our Latest Stock Analysis on Apellis Pharmaceuticals

Institutional Trading of Apellis Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Apellis Pharmaceuticals by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 9,555,678 shares of the company’s stock valued at $572,003,000 after acquiring an additional 85,701 shares in the last quarter. BlackRock Inc. increased its stake in shares of Apellis Pharmaceuticals by 1.0% in the 1st quarter. BlackRock Inc. now owns 5,923,920 shares of the company’s stock valued at $300,993,000 after acquiring an additional 58,208 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its stake in Apellis Pharmaceuticals by 5.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 5,842,660 shares of the company’s stock valued at $302,124,000 after purchasing an additional 326,537 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Apellis Pharmaceuticals by 66.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,590,040 shares of the company’s stock valued at $302,760,000 after purchasing an additional 1,840,498 shares in the last quarter. Finally, Jennison Associates LLC increased its stake in Apellis Pharmaceuticals by 79.8% during the 3rd quarter. Jennison Associates LLC now owns 3,542,209 shares of the company’s stock valued at $134,746,000 after purchasing an additional 1,571,606 shares in the last quarter. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

(Get Free Report)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

Featured Articles

Insider Buying and Selling by Quarter for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.